Pediatric Endocrinology: Hormonal Conditions in Children

Pediatric endocrinology addresses the diagnosis and management of hormonal disorders that arise during infancy, childhood, and adolescence — a population whose endocrine needs differ substantially from those of adults because growth, puberty, and metabolic development are ongoing biological processes. Conditions affecting the thyroid, adrenal glands, pituitary, pancreas, and reproductive axis can alter a child's growth trajectory, neurological development, and long-term metabolic health if left unmanaged. This page covers the scope of the subspecialty, the mechanisms underlying common pediatric hormonal disorders, the clinical presentations most frequently encountered, and the criteria that guide specialist referral and management decisions. The Endocrinology Authority home provides broader context on the endocrine system and its clinical relevance across the lifespan.

Definition and Scope

Pediatric endocrinology is a board-certified subspecialty of pediatrics, recognized by the American Board of Pediatrics (ABP), that focuses exclusively on disorders of hormone-secreting glands in patients from birth through late adolescence. The subspecialty encompasses conditions of the hypothalamic-pituitary axis, thyroid, parathyroid, adrenal cortex and medulla, gonads, and endocrine pancreas.

The distinction from adult endocrinology is not merely age-based. Growing organs respond differently to hormonal excess or deficiency, and diagnostic reference ranges shift with Tanner stage, bone age, and chronological age. A thyroid-stimulating hormone (TSH) value considered normal in a 35-year-old adult may be pathological in a 6-week-old infant, where thyroid hormone is essential for brain myelination. The American Academy of Pediatrics (AAP) and the Pediatric Endocrine Society (PES) both publish condition-specific clinical practice guidelines that account for these developmental variables.

Regulatory framing for pediatric endocrine care is shaped by the Centers for Medicare & Medicaid Services (CMS) through its Medicaid Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) mandate, which requires comprehensive screening for conditions including congenital hypothyroidism and congenital adrenal hyperplasia (CAH) in all Medicaid-eligible children. The regulatory context for endocrinology provides additional detail on how federal and state frameworks govern endocrine screening programs.

How It Works

Pediatric endocrine evaluation follows a structured diagnostic pathway that integrates clinical assessment, biochemical testing, and imaging within age- and stage-specific reference frameworks.

Core diagnostic phases:

1. Growth and pubertal staging — Height velocity, weight trajectory, and Tanner staging establish whether a child is developing along expected curves. Deviations trigger targeted hormone panels.
2. Biochemical screening — Serum panels vary by suspected condition. Congenital hypothyroidism newborn screening measures TSH and free T4 within the first 48–72 hours of life in all 50 US states, per state public health mandates aligned with the Recommended Uniform Screening Panel (RUSP) maintained by the Health Resources and Services Administration (HRSA).
3. Stimulation and suppression testing — Unlike adults, children with suspected growth hormone deficiency require formal stimulation testing (e.g., glucagon or arginine stimulation) because random growth hormone levels are uninformative due to pulsatile secretion. The PES publishes consensus thresholds for defining a growth hormone response as deficient.
4. Bone age radiography — A left-hand radiograph compared to the Greulich-Pyle atlas assigns a skeletal maturation estimate that can be months or years ahead of or behind chronological age, directly informing treatment decisions in short stature and precocious puberty.
5. Imaging — Pituitary MRI, thyroid ultrasound, and adrenal imaging are sequenced based on biochemical findings, not used as first-line screens.
6. Genetic evaluation — Disorders such as Turner syndrome (45,X karyotype), Klinefelter syndrome (47,XXY), and CAH involve chromosomal or single-gene defects that require coordination with clinical genetics.

The mechanism of pediatric endocrine disease parallels adult pathophysiology — hormone excess, deficiency, resistance, or ectopic production — but the consequences manifest through disrupted growth and developmental milestones rather than, or in addition to, the metabolic complications seen in adults.

Common Scenarios

The following conditions represent the highest-prevalence diagnoses managed within pediatric endocrinology practices in the United States, according to the Pediatric Endocrine Society:

• Type 1 Diabetes — The dominant form of diabetes in children. The American Diabetes Association (ADA) reports that approximately 1 in every 300 children in the US will develop type 1 diabetes by age 18, driven by autoimmune destruction of pancreatic beta cells. Management centers on insulin therapy, increasingly delivered via continuous glucose monitoring integrated with insulin pump systems.
• Type 2 Diabetes — Rates in pediatric populations rose sharply over the two decades preceding 2023. The SEARCH for Diabetes in Youth study, funded by CDC and NIDDK, documented a 95% increase in pediatric type 2 diabetes incidence between 2002 and 2015.
• Hypothyroidism — Congenital hypothyroidism affects approximately 1 in 2,000–4,000 newborns in the US (HRSA, RUSP documentation). Acquired autoimmune (Hashimoto's) thyroiditis is the leading cause of hypothyroidism in children over age 6.
• Growth hormone deficiency — Diagnosed in roughly 1 in 3,500 children, requiring recombinant human growth hormone therapy approved by the FDA for this indication.
• Precocious puberty — Defined as puberty onset before age 8 in girls and age 9 in boys (Lawson Wilkins Pediatric Endocrine Society criteria). Central precocious puberty is managed with GnRH agonists to preserve adult height potential.
• Congenital adrenal hyperplasia (CAH) — The most common adrenal disorder in children; 21-hydroxylase deficiency accounts for over 90% of CAH cases (Merke & Bornstein, New England Journal of Medicine, cited in NIH/NICHD resources).
• Hyperthyroidism and Graves' disease — Less common than hypothyroidism in children but clinically significant; Graves' disease accounts for approximately 95% of pediatric hyperthyroidism cases.

Decision Boundaries

Determining when a child's hormonal presentation requires subspecialty evaluation — rather than continued primary care monitoring — follows criteria established by the AAP and PES.

Refer to a pediatric endocrinologist when:

1. Height velocity falls below the 25th percentile for age and sex over a 6-month observation period, or height is below the 3rd percentile with no familial explanation.
2. Puberty onset occurs before age 8 (girls) or age 9 (boys), or is absent by age 13 (girls) or 14 (boys).
3. Newborn screening returns an abnormal TSH or 17-hydroxyprogesterone value — both RUSP-mandated screens require confirmatory follow-up within defined time windows.
4. Fasting glucose meets ADA diagnostic criteria for diabetes (≥126 mg/dL on two separate occasions) or HbA1c reaches ≥6.5%.
5. An incidentally discovered adrenal or thyroid mass requires staging under endocrine-oncology protocols.
6. A child with known type 1 diabetes demonstrates loss of glycemic control that cannot be stabilized within primary care resources.

Contrast: Pediatric vs. Adult Endocrine Decision Thresholds

Safety standards for pediatric radiation exposure during imaging follow the ALARA (As Low As Reasonably Achievable) principle, codified under guidelines from the American College of Radiology (ACR) and the Image Gently Alliance, which specifically addresses dose reduction in children undergoing CT and nuclear medicine studies relevant to adrenal and thyroid evaluation.

References

• Pediatric Endocrine Society (PES) — Clinical Practice Guidelines
• American Board of Pediatrics — Subspecialty Certification in Pediatric Endocrinology
• American Academy of Pediatrics (AAP) — Endocrinology Clinical Practice Policies
• Health Resources and Services Administration (HRSA) — Recommended Uniform Screening Panel (RUSP)
• American Diabetes Association — Standards of Medical Care in Diabetes
• [SEARCH for

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)